Renal transplantation

Indian Journal of Pediatrics

Volumn 70, Issue 3, 2003, Pages 257-264

  Moudgil, Asha ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Allograft; End stage renal disease; Immunosuppression

Indexed keywords

ANTIBODY; AZATHIOPRINE; CD3 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIBODY; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGRAFT; ANEMIA; BACTERIAL INFECTION; BLOOD COMPATIBILITY; BLOOD GROUP ABO SYSTEM; CANCER INCIDENCE; CARCINOMA; CHILD GROWTH; CHILD NUTRITION; CHRONIC HEPATITIS; CONFERENCE PAPER; DEVELOPING COUNTRY; DISEASE COURSE; DONOR; DRUG MECHANISM; ERYTHROCYTOSIS; GENETIC DIFFERENCE; GLOMERULONEPHRITIS; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCALCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INTRAOPERATIVE PERIOD; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ACIDOSIS; LEUKOPENIA; LIVING DONOR; METABOLIC DISORDER; NERVE CELL DIFFERENTIATION; NEUROLOGIC DISEASE; OXALOSIS; PATIENT CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; QUALITY OF LIFE; RECURRENT DISEASE; SIDE EFFECT; SOCIOECONOMICS; SURGICAL TECHNIQUE; SURVIVAL; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VIRUS INFECTION;

EID: 0037989879     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02725594     Document Type: Conference Paper

References (28)

1. Hariharan S. Long-term kidney transplant survival. Am J Kidney Dis 2001; 38: S 44-50.
2. [No authors listed] IV. 11 Pediatrics (specific problems). Nephrol Dial Transplant 2002; 17 (Suppl 4): 55-58.
3. Saieh-Andonie C. The management of end-stage renal disease in underdeveloped countries: a moral and economic problem. Pediatr Nephrol 1990; 2: 199-201.
4. Strom TB. Immunosuppression in tissue and organ transplantation. In Brent and Sells, eds. Current Clinical and Immunologic Concepts in Organ Transplantation. Lislie Balliere Tindall Inc. London, 1989; 39-59.
5. Kerman RH. Relevance of histocompatibility testing in clinical transplantation. Surg Clin North Am 1994; 74: 1015-1028.
6. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353: 1083-1110.
7. Gourishankar S, Turner P, Halloran P. New developments in immunosuppressive therapy in renal transplantation. Expert Opin Biol Ther 2002; 2: 483-501.
8. Kasiske BL, Congro CB, Hariharan S et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2002; (1 Suppl 2): 1-95.
9. Abesassis M, Adams M, Adams P et al. Consensus statement on the live organ donor. JAMA 2000; 284: 919-926.
10. Shapiro R. The transplant procedure. In Shapiro R, Simmons RL, Starzl TE, eds. Renal Transplantation. Appleton and Lange, Stamford, CT 1997; 103-141.
11. Fishman JA, Rubin RH. Infection in organ transplant recipients. N Eng J Med 1998; 338: 1744-1751.
12. DeMattos AM, Norman DJ. OKT3 for treatment of rejection in renal transplantation. Clin Transplant 1993; 7: 374-381.
13. Moudgil A, Shidban H, Nast CC et al. Parvovirus B 19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation 1997; 64: 1847-1850.
14. Hirsch HH. Polyomavirus BK nephropathy: a (re-) emerging complication in renal transplantation. Am J Transplant 2002; 2 : 25-30.
15. Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis 2001; 38: 919-934.
16. Lattes R, Radisic M, Rial M, Argento J, Casadei D. Tuberculosis in renal transplant recipients. Transplant Infect Dis 1999; 1(2): 98-104.
17. [No authors listed] IV. 5.2 Arterial hypertension. Nephrol Dial Transplant 2002; 17: (Suppl 4): 25-26.
18. [No authors listed] IV.9.3 Erythrocytosis. Nephrol Dial Transplant 2002; 17(Suppl 4): 49-50.
19. Hariharan S. Recurrent and de novo diseases after renal transplantation. Semin Dial 2002; 13: 195-199.
20. Greenstein SM, Delrio M, Ong E et al. Plasmapheresis treatment for recurrent focal sclerosis in pediatric renal allografts. Pediatr Nephrol 2000; 12: 1061-1065
21. Qvist E, Marttinen E, Ronnholm K et al. Growth after renal transplantation in infancy or early childhood. Pediatr Nephrol 2002; 17: 438-443.
22. [No authors listed] IV.4 Noncompliance. Nephrol Dial Transplant 2002; 17 (Suppl 4): 23-24.
23. Dahrnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 71: 1065-1068.
24. Qvist E, Pihko H, Fagerudd P, Valanne L et al. Neurodevelopmental outcome in high-risk patients after renal transplantation in early childhood. Pediatr Transplant 2002; 6: 53-62.
25. Vincenti F, Kirkman R, Light S et al. Interleukin-2 receptor blockade with dacluzimab to prevent acute rejection in renal transplantation. N Eng J Med 1998; 338: 161-165.
26. Swiatecka-Urban A, Garcia C, Feuerstein D et al. Basiliximab induction improves the outcome of renal transplants in children and adolescents. Pediatr Nephrol 2001; 16: 693-696.
27. Shapiro R, Scantlebury VP, Jordan ML. Tacrolimus in Pediatric Renal Transplantation. Transplantation 1996; 62: 1752-1758.
28. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356: 194-202.